Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
Conditions
Interventions
Burosumab
Locations
3
United States
Yale University School of Medicine
New Haven, Connecticut, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
Shriners Hospital for Children
St Louis, Missouri, United States
Start Date
May 5, 2016
Primary Completion Date
April 20, 2017
Completion Date
September 10, 2019
Last Updated
May 6, 2024
NCT03745521
NCT03775187
NCT04188964
NCT04842032
NCT02537431
NCT01571596
Lead Sponsor
Kyowa Kirin, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions